There have been guidelines issued, such as Korean practice guidelines for gastric cancer, which recommend the assessment of Her2 status before the initiation of systemic chemotherapy, and, if possible, re-evaluation for recurrent or metastatic lesions [13]. This evidence concerns the gene ERBB2 and gastric cancer.